In this special report, we provide a summary of the highlights from the 10th annual Immuno-Oncology 360° (IO360°), February 27-29, 2024 at the New York Marriott at the Brooklyn Bridge, in Brooklyn, NY.

Marking a decade of IO360°, the summit brought together leaders from the science and business communities for a comprehensive program focused on data-driven advancements in immuno-oncology.

Day One’s opening keynote, Dr Taha Merghoub, Weill Cornell Medicine, outlined the history of IO, looking beyond PD-1 towards future clinical evolution, and potential mechanisms to enhance the potency of IO. Keynote Dr Laura Esserman, University of California San Francisco, presented how she had used neoadjuvant strategies to assess IO candidates, through her I-SPY trial platform. Dr Ira Mellman, Genentech, gave a keynote on combining AI and empirical science; Dr Alex Snyder, Generate Biomedicines, gave a visionary talk how generative AI can directly impact how drugs are developed, and a panel discussion focused on how to use AI to leverage data from the clinic to iterate next-generation drugs. Day One also included the second-annual Women Leaders in IO Luncheon and Panel Discussion.

Day Two began with an Analyst Keynote from Dr Andrew Baum, Citi, who spoke about what’s next on the IO radar, including an updated list of his top 10 recommendations. Zeitgeist Talk Dr Jason Luke, University of Pittsburgh/UPMC Hillman Cancer Center, traced the last decade of IO to pull lessons on IO biomarkers for target discovery, differentiating mechanisms and IO resistance biology. With patient advocate Cindy Geoghegan, Kelly Spill-Bonito told the story of how an immunotherapy trial saved her life and preserved her ability to have a family. Kalli Dircks, Morgan Stanley, spoke about the biotech markets and IO outlook. Rajiv Kaul, Fidelity Investments, discussed public investing in a difficult IPO market. The day ended with the annual IO360° Debate on the top next-gen approaches to challenges in cancer immunotherapy.

For Day Three, CEO Keynote Dr Patrick Hwu, Moffitt Cancer Center, used his expertise and deep experience in tumor-infiltrating lymphocytes, to discuss his lab’s work and the future of TIL therapy. Keynote Dr Margaret Callahan, University of Connecticut, gave a historical perspective of tumor vaccines and pivoted to the future, where the newest RNA vaccines could find success. Dr Tanya Keenan, Merck, gave a systematic evaluation of TIGIT. Dr Mai-Britt Zocca, IO Biotech, gave an update on immune-modulating cancer vaccines. Dr Rachel Salazar, Bicara Therapeutics, discussed tumor-targeting with a focus on TGFβ. Dr Benoit Rousseau, Memorial Sloan Kettering Cancer Center, closed the program with a dostarlimab data update for MSI-high rectal cancer.

Across the three days, there were panel discussions on how to use AI to leverage data from patients in the clinic to iterate next-gen immunotherapies; leveraging the rise of Chinese biotechs in IO; investment trends in IO; key learnings from manufacturing to help accelerate the process and development of cancer cell-based immunotherapies; synergizing radiopharmaceutical therapy and immunotherapy for optimal cancer treatment outcomes; unlocking the potential of ctDNA for prognostic stratification, tumor evolution insights, and accelerated drug development.

Across multiple tracks, IO360° speakers presented on discovery, preclinical & payload modification; translational science, imaging & biomarkers; IO cell therapy; cell therapy: discovery hypothesis generating data; cell therapy: data from the clinic; and IO and cell therapy clinical developments.

We are pleased to share highlights from IO360° 2024 and also provide recommended media and upcoming events. A big thank you to everyone who participated in this year’s event.

Sincerely,
The IO360° team,

Danny McCarthy
Multimedia Editor

Kate Woda
Senior Director

Valerie Bowling
Executive Director

Meredith Sands
Executive Director, Strategic Partnerships

BreAnna Bugbee
Senior Marketing Manager

Adam Kolanko
Senior Strategic Partnership Manager

Elizabeth Bard
Senior Strategic Partnership Manager

Shelby Casabura
Strategic Partnership Manager

Eliza Brooks
Digital Media and Ad Sales Associate
IMMUNO-ONCOLOGY 360° Photo Gallery

For more photos, [click here](link)
IO360° Photo Gallery

For more photos, click here
IO360° Speaking Faculty Shines

Keynotes
- **Taha Merghoub, PhD**, Deputy Director, Sandra and Edward Meyer Cancer Center / Margaret and Herman Sokol Professor of Oncology Research / Professor of Pharmacology and Professor of Immunology Research in Medicine, Weill Cornell Medicine
- **Laura Esserman, MD, MBA**, Professor of Surgery & Radiology / Director, University of California, San Francisco/UCSF Carol Franc Buck Breast Cancer Center
- **Ira Mellman, PhD**, VP, Cancer Immunology, Genentech
- **Andrew Baum, MD**, Head of Global Healthcare; Managing Director, Equity Research, Citi
- **Kristen Hege, MD**, Independent Board Member, Adaptimmune, Mersana & Graphite Bio,
- **Patrick Hwu, MD**, President and CEO, Moffitt Cancer Center
- **Margaret Callahan, MD, PhD**, Chief, Division of Hematology/Oncology, Associate Professor, University of Connecticut

Opening Remarks
- **Axel Hoos, MD, PhD**, Former CEO, Scorpion Therapeutics
- **James Gulley, MD, PhD, FACP**, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
- **Priti Hegde, PhD**, SVP and Global Head of Research, Kite Pharma, a Gilead Company

Plenary Chairs and Track Chairs
- **Priti Hegde, PhD**, SVP and Global Head of Research, Kite Pharma, a Gilead Company
- **Alex Snyder, MD**, EVP, Research and Development, Generate Biomedicines
- **David Leung, MD, PhD**, Head of Imaging, Daiichi Sankyo
- **Jacqueline Karmel**, Chair, imCORE Executive Office & Principal International Scientific Director, Cancer Immunotherapy, Roche
- **James Gulley, MD, PhD, FACP**, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
- **Marisa Dolled-Filhart, PhD**, VP, Translational Research, Cancer Immunology and Cell Therapy Thematic Research Center, BMS
- **Graig C. Suvannavejh**, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA
- **Asthika Goonewardene, MBA**, Managing Director, Senior Biotech Analyst, Truist Securities
- **David Feltquate, MD, PhD**, CMO, Palleon Pharmaceuticals
- **Michael Kalos, PhD**, Managing Director, Next Pillar Consulting
- **Rosanna Ricafort, MD**, VP and Head, Hematology and Cellular Therapy Development, BMS
- **Theresa LaVallee, PhD**, Chief Development Officer, Coherus BioSciences
- **Maria Jure-Kunkel, DVM, PhD**, VP, Translational Medicine, Genmab
- **Vanessa Lucey, PhD, MBA**, Director, WW Oncology Commercialization, Early Assets, BMS
- **Raluca Verona, PhD**, Head, Oncology Precision Medicine Group, AbbVie

“It truly was a knock-out conference. I’m honored to be part of it!”
- Alex Snyder, MD, Generate Biomedicines
IO360° Speaking Faculty Shines

Annual Debate
- Alex Snyder, MD, EVP, Research and Development, Generate Biomedicines
- Michael Kalos, PhD, Managing Director, Next Pillar Consulting
- Charles Drake, MD, PhD, VP, Immuno-Oncology, J&J Innovative Medicine
- Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
- Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
- Naiyer Rizvi, MD, CMO, Synthekine
- William Ho, MBA, President & CEO, IN8Bio

Progress Update on KEYNOTE-671: A Perioperative Treatment for NSCLC
- Gregory Lubiniecki, MD, VP, Clinical Oncology, Merck

Utilization of IO Agents in Adjuvant Disease
- Alexander Eggermont, MD, PhD, CSO / Professor, Clinical & Translational Immunotherapy, Princess Máxima Center for Pediatric Oncology / UMC Utrecht, Utrecht University

Optimization of Neoantigen Targets for Shared and Personalized Anti-Cancer Vaccines
- Michelle Krogsgaard, PhD, Associate Professor of Pathology / Director of Tumor Immunology Program / Graduate Advisor Inflammation and Immunology Program, Department of Pathology, Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine

Update on BioNTech Adjuvant Vaccine Studies
- Mark DeMario, MD, MPH, VP, Clinical Development, BioNTech US

IO Novel Technologies Showcase
- Sean Carlin, PhD, Principal Scientist, Scientific and Medical Services, Invicro
- Adam Laing, PhD, Co-Founder & CEO, IMU Biosciences
- Erin Trachet, Senior Director, Scientific Engagement, TD2
- Emily Adney-Holt, PhD, Technical Sales Specialist, Lunaphore Technologies
- Wim Vos, PhD, CEO, Radiomics
- Dongxiao Feng, VP of Business Development, Shanghai Model Organisms
- Tim Sindelar, MS, Product Manager, Spatial Biology, Canopy Biosciences
- Anders Haegerstrand, MD, PhD, CEO, Annexin Pharmaceuticals
- Ramji Srinivasan, Co-founder and CEO, Teiko Bio
- Selena Larkin, PhD, MBA, Chief Commercial Officer, RareCyte
- Marissa Fahlberg, PhD, Director of Applications, LASE Innovation
- Julianna Collins, Director, Business Development, Voiant
- Rhea Chitalia, PhD, Scientific Partnerships Manager, Picture Health
- Marie Cumberbatch, Head of IO Applications and Projects, TriStar Technology Group

“I greatly enjoyed the conference and the many opportunities to form collaborative connections. Thank you for the opportunity to present and for organizing a very successful event!”
- Allison Kaeding, MD, BMS
**IO360° Speaking Faculty Shines**

**Women Leaders in IO: Mentoring and Mentorships Panel**
- **Mara Goldstein**, Former Managing Director, Biotechnology Analyst, Mizuho Securities
- **Shubh Goel**, VP, Head of Immuno-Oncology and Gastrointestinal (GI) Tumors Franchise, US Oncology Business Unit, AstraZeneca
- **Marisa Dolled-Filhart**, PhD, VP, Translational Research, Cancer Immunology and Cell Therapy Thematic Research Center, BMS
- **Julie Martin**, MSc, MBA, CEO & Co-Owner, Scimega Research
- **Noor Jailkhani**, PhD, CEO and Co-Founder, Matrisome Bio
- **Raluca Verona**, PhD, Head, Oncology Precision Medicine Group, AbbVie

**Visionary Talk: How will Generative AI Directly Impact How IO Drugs are Developed?**
- **Alex Snyder**, MD, EVP, Research and Development, Generate Biomedicines

**How to Use AI to Leverage Data from Patients in the Clinic to Iterate Next Gen Immunotherapies**
- **Alex Snyder**, MD, EVP, Research and Development, Generate Biomedicines
- **Ira Mellman**, PhD, VP, Cancer Immunology, Genentech
- **Sharon Benzeno**, PhD, MBA, Chief Commercial Officer, Immune Medicine, Adaptive Biotechnologies
- **Adeeb Rahman**, PhD, VP, Platform Architecture, Immunai
- **Andrew Allen**, MD, PhD, President & CEO, Gritstone bio, Inc.

**Discovery, Preclinical & Payload Modification**
- **Dawn Colburn**, PharmD, BCOP, Vice President, Clinical Development, Bolt Biotherapeutics
- **Tehila Ben Moshe**, PhD, CEO, Biond Biologics
- **Peter DeMuth**, PhD, CSO, Elicio Therapeutics
- **Oliver Rosen**, MD, CMO, Akamis Bio
- **James Moon**, PhD, JG Searle Professor of Pharmaceutical Sciences; Biomedical Engineering and Chemical Engineering, Biointerfaces Institute, University of Michigan
- **Stephen Thorne**, PhD, CSO, Kalivir Immunotherapies
- **B. Dusty Majumdar**, PhD, CEO, PredxBio
- **Mark Frattini**, MD, PhD, CMO, Cellectis, Inc

“Thanks for organizing another fantastic meeting; it's really a unique setting that brings science, biotech and pharma together.”
- Charles Drake, MD, PhD, J&J innovative Medicine

“Congratulations to you and your team for organizing an incredible event. I very much enjoyed my time at the conference and looking forward to going back to Boston for this next year.”
- Saman Maleki, PhD, University of Western Ontario
IO360° Speaking Faculty Shines

Translational Science, Imaging and Biomarkers
- Moitreyee Chatterjee-Kishor, PhD, MBA, Head, Immuno Oncology and Cell Therapy Development, Astellas Pharma US
- Elaine Long, PhD, Scientific Leader, Immuno-Oncology, GE Healthcare
- Oscar Puig, PhD, VP, Translational Medicine and Diagnostics, Nucleai
- Christine Schubert-Wagner, PhD, MBA, CSO, CatalYm GmbH
- Siraj Ali, MD, PhD, Global Vice President, Translational Medicine, Lunit
- Nathalie Toussenel, Executive Director, Project Management, Clinical Research, PPD, part of Thermo Fisher Scientific
- Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck
- Robert Meehan, MD, Senior Director, Clinical Development, Moderna
- Saman Maleki, PhD, Assistant Professor, Ontario Institute for Cancer Research, University of Western Ontario
- Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)
- Jan Wolber, PhD, Global Product Leader Digital Pharmaceutical Diagnostics, GE Healthcare
- Travis Osterman, DO, Assistant Professor, Department of Biomedical Informatics, Assistant Professor, Division of Hematology and Oncology / Director or Cancer Clinical Informatics, Vanderbilt University Medical Center/ Vanderbilt-Ingram Cancer Center
- David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
- Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
- Ohad Ilovich, PhD, Director, Head of Clinical Imaging, Amgen
- Elaine Long, PhD, Scientific Leader, Immuno-Oncology, GE Healthcare
- Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
- Jack Hoppin, PhD, Founder and CEO, Ratio Therapeutics
- Ron Korn, MD, PhD, Founder and CMO, Imaging Endpoints
- Antoine Iannessi, MD, Head of Medical Affairs, iCRO Business Unit, Median Technologies
- Matthew Silver, PhD, Head, Companion Diagnostics, Takeda
- John Simmons, PhD, Global VP, Biopharma Partnerships, Natera
- Reshma Patel, Director and Global Regulatory Lead, J&J Innovative Medicine
- Jeff Allen, PhD, CEO & President, Friends of Cancer Research (FOCR)

Zeitgeist Talk: Immuno-Oncology Lessons from the Past 10 Years that Can Help Advance Cancer Immunotherapies:
- Jason Luke, MD, FACP, Associate Director for Clinical Research and Director, Immunotherapy and Drug Development Center / Associate Professor of Medicine, UPMC Hillman Cancer / Center University of Pittsburgh

Fireside Patient Chat: The Personal Impact of an Immunotherapy Trial
- Kelly Spill-Bonito, Patient Advocate
- Cindy Geoghegan, Patient Advocate

“I thought the debate was very original, and a good way to talk about the field. I appreciated the combination of topics and expert opinions.”
– Beatriz Aranda Orgilles, PhD, Cellectis
IO360° Speaking Faculty Shines

Biotech Markets & IO Outlook
- Kalli Dircks, Managing Director, Global Capital Markets, Morgan Stanley

Biotech Showcases
- David Burkhart, PhD, COO, Inimmune
- Livija Deban, PhD, CSO, Prokarium
- Nathanael McCurley, PhD, VP, Research and Development, SIRPant Immunotherapeutics
- Jay Fine, PhD, President, Research & Development, EvolveImmune Therapeutics
- Joanne Hulme, PhD, CSO, Radiant Biotherapeutics
- Hongtao Lu, PhD, Co-Founder & CSO, Elpiscience
- William Jia, PhD, CSO & Co-founder, Virogin
- Tehila Ben Moshe, PhD, CEO, Biond Biologics
- Matthew Martin, PhD, MBA, CEO, Saros Therapeutics
- Lars Prestegarden, CEO, Cytovation

Fireside Chat: Public Investing in a Difficult IPO Market
- Rajiv Kaul, Portfolio Manager, Equity Division, Fidelity Investments
- Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics

Leveraging the Rise of China Biotech in IO: Pros & Cons
- Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
- Leon ‘Jun’ Tang, PhD, Founder / Scientific Advisor, InScienceWeTrust BioAdvisory / Mianus Capital
- Jing Li, MD, PhD, MBA, Founder, CEO, VelaVigo
- Jie Liu, MBA, Managing Director, STIFEL
- Leo MacDonald, MBA, VP, BD Transactions - Hematology & I/O, J&J Innovative Medicine

Investment Trends in IO Panel
- Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
- Irina Margine, PhD, Principal, Biotech Private Equity, Wellington Management
- Khalil Barrage, Managing Partner, Invus Group
- Jeffrey Bockman, PhD, EVP, Oncology and Virology Practices, Lumanity
- Emmett Schmidt, MD, PhD, VP, Clinical Oncology, External Collaborations, Merck
- Gayatri Varma, PhD, Executive Director and Head of Transactions, Oncology R&D, AstraZeneca

IO Cell Therapy
- Kristen Hege, MD, Independent Board Member, Adaptimmune, Mersana & Graphite Bio
- Mark Stewart, PhD, VP, Science Policy, Friends of Cancer Research (FOCR)
- Christine Brown, PhD, Deputy Director, T Cell Therapeutics Research Laboratory, Beckman Research Institute, City of Hope
- Bruce Levine, PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
- Arvind Natarajan, PhD, MBA, SVP, Process and Analytical Development, Iovance Biotherapeutics Inc.
- Greg Russotti, PhD, Chief Technology and Manufacturing Officer, Century Therapeutics
- Jessica Carmen, PhD, Vice President, Business Development, Kincell Bio
- Shishir Gadam, PhD, Chief Technical Officer, Cargo Therapeutics
- Angela Chen, PhD, Chief Business Officer, WuXi Advanced Therapies
IO360° Speaking Faculty Shines

Cell Therapy: Hypothesis Generating Data
- Caleb Lareau, PhD, Principal Investigator & Assistant Professor, Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center
- Mat Legut, PhD, CEO, OverT Bio
- Kanya Rajangam, MD, PhD, Head, R&D and CMO, Senti Bio

Cell Therapy: Data from the Clinic
- Serena De Vita, MD, PhD, Global Head of Hematology, Translational Clinical Oncology, Novartis Institutes for BioMedical Research (NIBR)
- Diana Stoycheva, PhD, Principal Scientist, Scailyte AG
- Marco Ruella, MD, Assistant Professor of Medicine, Scientific Dir. Lymphoma Program, Division of Hematology and Oncology and Center for Cellular Immunotherapies, University of Pennsylvania
- Allison Kaeding, MD, Senior Director, Early Clinical Development: IO and Cell Therapy, BMS

IO and Cell Therapy Clinical Developments
- Sergio Quezada, PhD, Professor of Cancer Immunology and Immunotherapy / CSO, University College London Cancer Institute / Achilles Therapeutics
- Erin Karski, MD, Executive Medical Director, Cell Therapy, Early Oncology R&D, AstraZeneca
- Tonia Nesheiwat, Pharmed, VP, Medical Affairs, Caribou Biosciences
- Harpreet Singh, PhD, CEO, Immatics
- Edward van der Horst, PhD, CSO, Sensei Bio
- Gulam Manji, MD, PhD, Associate Professor of Medicine, Columbia University Irving Medical Center
- Dejan Knezevic, PhD, Senior Business Development Director, Guardant Health
- Blake Aftab, PhD, CSO, Adicet Bio
- Judd Englert, MD, PhD, Executive Medical Director, Oncology, Amgen
- Roy Baynes, MD, PhD, EVP & CMO, Eikon Therapeutics
- Dirk Brockstedt, PhD, CSO, RAPT Therapeutics, Inc.
- John Mumm, PhD, CEO, DEKA Biosciences

Systematic Evaluation of TIGIT
- Tanya Keenan, MD, MPH, Executive Director, Oncology Clinical Development, Merck

Update on IO Biotech’s Immune Modulating Cancer Vaccine
- Mai-Britt Zocca, PhD, Founder and CEO, IO Biotech

Tumor Targeted IO - Right Target, Right Tumor, Right Modality, a Focus on TGFβ
- Rachel Salazar, DHSc, SVP, R&D Strategy & Operations, Bicara Therapeutics

Dostarlimab Data Update for MSI-High Rectal Cancer
- Benoit Rousseau, MD, PhD, Assistant Attending Physician / Assistant Lab Member, Memorial Sloan Kettering Cancer Center

“It was an absolute pleasure and a fantastic meeting. I’m looking forward to the 2025 meeting in Boston.”
- Dushen Chetty, PhD, Novartis
Thank you to the IO360° 2024 Sponsoring Companies
Immuno-Oncology 360°

Celebrating 10 Years

Annual Event

Digital Editorial

Year-Round Podcasts and Webcasts

WWW.IO360SUMMIT.COM